Hypertension is the leading modifiable cause of premature death and hence one of the
global targets of World Health Organization for prevention. Hypertension also affects the …

SGLT2 inhibitors have emerged as a key disease-modifying therapy to prevent the
progression of chronic kidney disease (CKD). These agents prevent decline in kidney …

Background Large trials have shown that sodium glucose co-transporter-2 (SGLT2)
inhibitors reduce the risk of adverse kidney and cardiovascular outcomes in patients with …

Background An unmet need exists for focal segmental glomerulosclerosis (FSGS) treatment.
In an 8-week, phase 2 trial, sparsentan, a dual endothelin–angiotensin receptor antagonist …

Background The effects of the sodium-glucose co-transporter 2 inhibitor empagliflozin on
renal and cardiovascular disease have not been tested in a dedicated population of people …

Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) were originally developed as
antidiabetic agents, with cardiovascular (CV) outcome trials demonstrating improved CV …

Albuminuria, a hallmark of diabetic nephropathy, reflects not only injury and dysfunction of
the filtration apparatus, but is also affected by altered glomerular hemodynamics and …

Diabetes drives an increasing burden of cardiovascular and renal disease worldwide,
motivating the search for new hypoglycemic agents that confer cardiac and renal protective …

Chronic kidney disease (CKD) is a major public health issue affecting an estimated 850
million people globally. The leading causes of CKD is diabetes and hypertension, which …

Results from recent randomized controlled trials on inhibitors of the sodium-glucose
cotransporter 2 (SGLT2) have determined a paradigm shift in the treatment of patients with …